Brief: Pulse Biosciences Announces FDA IDE Approval To Initiate Its nsPFA Cardiac Surgery System Study For The Treatment Of Atrial Fibrillation
08/09/2025 12:42
Sept 8 (Reuters) - Pulse Biosciences Inc PLSE.O: PULSE BIOSCIENCES ANNOUNCES FDA IDE APPROVAL TO INITIATE ITS NSPFA CARDIAC SURGERY SYSTEM STUDY FOR THE TREATMENT OF ATRIAL FIBRILLATION Source text: ID:nBw8LzHyYa Further company coverage: PLSE.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Pulse Biosciences
See all newsBrief: Pulse Biosciences, Inc. Announces Planned Redemption Of Warrants
Chairmen Total Approximately $13.3 Million
Pulse Biosciences records Q1 revenue, but loss widens on higher clinical investment
Brief: Pulse Biosciences Q1 Net Income USD -18.581 Million
Brief: Pulse Biosciences Announces Positive Clinical Data From Npulse Cardiac Catheter System